This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D56.4 | Synonyms: HPFH, hereditary persistence of fetal hemoglobin, Hereditary persistence of HbF
Hereditary persistence of fetal hemoglobin (HPFH) was first described in 1955 when Edington and Lehmann reported cases in the population of Ghana, Africa, in which HbF remained abnormally high into adulthood. They were the first to point out that this phenomenon is observed in clinically healthy individuals and differs from common thalassemia or other hemoglobin abnormalities.
In the 1950s~1960s, Huisman, Schroeder, and others systematically described the types of HPFH in various ethnic groups. It was established that HPFH found in populations of African descent (HPFH-1, HPFH-2) shows a pancellular HbF distribution, whereas the form found in the Greek population (Greek HPFH) and some point-mutation types show a heterocellular distribution.
In the 1980s~1990s, Forget, Stamatoyannopoulos, and others elucidated the molecular basis of HPFH. In deletional HPFH, they confirmed that large deletions in the beta-globin gene cluster remove the repressive regulatory sequences of the γ genes, so that γ-globin expression persists into adulthood. In nondeletional HPFH, they showed that point mutations within the γ gene promoters interfere with repression of γ-globin expression.
Since 2008, genome-wide association study (GWAS) research has shown that genes such as BCL11A, KLF1, HBS1L-MYB are key regulators of γ-globin expression. This discovery became the theoretical foundation for developing HbF induction treatment strategies, and gene therapy based on BCL11A suppression has entered the clinical development stage.
In deletional HPFH, a large deletion occurs in the beta-globin gene cluster on the short arm of chromosome 11, removing not only the δ and β genes but also the 3' regulatory sequences that repress γ-globin expression, so that γ-globin continues to be expressed into adulthood. Major deletion types: HPFH-1 (African type, deletion of about 105 kb), HPFH-2 (African type 2), HPFH-3 (Indian type), among others.
Nondeletional HPFH is caused by point mutations in the promoter region of the γ-globin genes (HBG1 or HBG2). These mutations disrupt the binding sites of transcriptional repressor proteins (BCL11A, KLF1, ZBTB7A) or enhance the binding of transcriptional activators, sustaining γ-globin expression in adulthood. Representative mutations: Gg-158 C>T (Greek HPFH), Ag-175 T>C, Ag-202 C>T, among others.
Common variants at the BCL11A, KLF1, and HBS1L-MYB loci explain the natural variation in HbF levels within populations and cause mild heterocellular HPFH in some individuals. This is related to the phenomenon of HbF levels varying in the 1~3% range in the general population.
Both deletional and nondeletional HPFH are inherited in an autosomal manner. Deletional HPFH shows fully dominant or codominant characteristics, with markedly elevated HbF in heterozygotes (15~30%). Homozygous deletional HPFH consists of 100% HbF and is clinically completely asymptomatic.
| Type | HbF level | HbA2 | HbF cellular distribution | Clinical findings |
|---|---|---|---|---|
| Deletional HPFH heterozygote | 15~30% | Decreased | Pancellular | Asymptomatic, mild microcytosis |
| Nondeletional HPFH heterozygote | 10~20% | Normal | Pancellular or heterocellular | Completely asymptomatic |
| Heterocellular HPFH | 1~10% | Normal | Heterocellular | Asymptomatic |
| Deletional HPFH homozygote | ~100% | Absent | Pancellular | Completely asymptomatic |
When HPFH is compound heterozygous with an HbS allele (HbS/HPFH), the high HbF inhibits HbS polymerization, so the clinical course is markedly milder than in simple HbSS disease. This provides the theoretical basis for HbF induction therapy.
The exact worldwide prevalence of HPFH is not well known. Deletional HPFH is reported rarely, particularly in African American, West African, East African, and Mediterranean populations. Nondeletional HPFH is reported in Greece, Southeast Asia, the Indian subcontinent, and elsewhere. Mild HbF elevation, including heterocellular HPFH, is observed in about 0.1~1% of the general population.
Systematic epidemiological data on HPFH in Korea are very scarce. In Korea, most cases are discovered incidentally during prenatal screening or hemoglobin abnormality surveys. With the increase in immigrants of Southeast Asian descent, cases of nondeletional HPFH are reported intermittently.
HPFH itself does not cause clinical disease, but when it occurs in a compound heterozygous state with other globin gene abnormalities, it acts as a clinically important phenotypic modifier. In addition, understanding of the regulatory mechanisms of HPFH is providing key insights for the development of HbF induction therapies.
In normal development, fetal hemoglobin consists mainly of HbF (alpha2gamma2), and around birth a switch from gamma to beta globin chain predominance (hemoglobin switching) occurs, so that by 6~12 months of age HbF is almost completely replaced by HbA. This switch is precisely regulated by transcription factors such as BCL11A, KLF1, MYB, LRF (ZBTB7A).
In deletional HPFH, the large deletion removes the repressive regulatory sequences downstream of the γ-globin genes and repositions a powerful 3' enhancer close to the γ genes. As a result, binding of repressors such as BCL11A is weakened in adult erythroid progenitor cells, and γ-globin continues to be expressed.
In nondeletional HPFH, point mutations in the γ-globin gene promoters disrupt the binding sites of repressive transcription factors such as BCL11A, KLF1, and ZBTB7A (LRF). This prevents the repressors from binding to the promoter, so that the γ-globin genes remain active into adulthood.
Even when HbF partially or completely replaces HbA in HPFH, HbF functions as a functional oxygen-carrying hemoglobin. HbF has a higher oxygen affinity than HbA, but it can still function adequately in supplying oxygen to adult tissues, so there are no clinical symptoms.
Simple HPFH (deletional or nondeletional, heterozygous or homozygous) is clinically completely asymptomatic. Although HbF remains high into adulthood, HbF itself is a functional oxygen-carrying hemoglobin, so symptoms such as anemia, jaundice, and splenomegaly do not develop.
Symptoms when HPFH is combined with beta-thalassemia or sickle cell genes vary greatly depending on the HbF level. In HPFH/HbS compound heterozygosity, when HbF is high at 15~30%, sickle hemoglobin polymerization is inhibited and symptoms may be mild or absent. In HPFH/beta0 compound heterozygosity, when HbF is sufficiently high (50% or more), a clinically mild thalassemia intermedia phenotype is seen.
When the HPFH gene coexists in patients with sickle cell disease or severe beta-thalassemia, it markedly ameliorates the clinical course. This provides the theoretical basis for HbF induction therapies (hydroxyurea, luspatercept, gene therapy).
In simple HPFH, the physical examination is completely normal. There are no findings such as splenomegaly, jaundice, pallor, or skeletal deformity. Homozygous deletional HPFH (HbF 100%) is also clinically normal.
Complete blood count (CBC): in heterozygous deletional HPFH, Hb normal to mildly decreased, MCV may be mildly decreased. In nondeletional HPFH, CBC mostly normal. HPLC: in heterozygous deletional HPFH, HbF 15~30%, HbA2 decreased. In nondeletional heterozygous HPFH, HbF 10~20%, HbA2 normal. In homozygous deletional HPFH, HbF 100%, no HbA or HbA2.
In deletional HPFH, all red blood cells contain HbF uniformly (pancellular distribution), whereas in nondeletional HPFH (heterocellular HPFH) and some nondeletional forms, the proportion of HbF-containing cells varies. HbF cellular distribution is confirmed by Kleihauer-Betke staining or flow cytometry.
HPFH is mostly discovered incidentally. When HbF is abnormally high in an adult on HPLC or hemoglobin electrophoresis (2~3% or more by adult standards), HPFH should be included in the differential diagnosis.
When HbF of 2~3% or more is found in an adult, causes of elevated HbF such as HPFH, delta-beta thalassemia, and beta-thalassemia are differentiated. The presence of microcytosis on CBC and the HbA2 level help in differentiation. In HPFH, HbF high and HbA2 normal or decreased; in beta-thalassemia, HbA2 elevated; in delta-beta thalassemia, HbA2 decreased + HbF elevated.
Molecular genetic testing (gap-PCR, MLPA, Sanger sequencing, NGS) confirms the deletion type or γ-promoter mutation. Kleihauer-Betke staining or flow cytometry evaluates the HbF cellular distribution (pancellular vs. heterocellular).
HPLC or capillary electrophoresis is the standard method for accurately quantifying HbF levels. In adults with HbF of 5% or more, HPFH or delta-beta thalassemia is strongly suspected. The combination of HbA2 level and MCV is essential for differential diagnosis.
Acid elution staining (Kleihauer-Betke) identifies HbF-containing cells on a blood smear; a pancellular pattern is observed in deletional HPFH and a heterocellular pattern in heterocellular HPFH. Flow cytometry quantifies the proportion and distribution of HbF cells more accurately.
Gap-PCR detects the major deletional HPFH types (HPFH-1, 2, 3) and the major delta-beta thalassemia deletion types. MLPA is useful for detecting atypical deletions. Sanger sequencing or NGS panels identify HBG1 and HBG2 promoter mutations to diagnose nondeletional HPFH.
Delta-beta thalassemia: HbF elevated, HbA2 decreased, microcytosis, confirmed by molecular testing. Beta-thalassemia trait: HbA2 elevated (3.5% or more), HbF mildly elevated. Transient erythroblastopenia or aplastic anemia: HbF transiently elevated. Heterocellular HPFH: HbF 1~10%, heterocellular pattern on Kleihauer-Betke.
Isolated HPFH is not a clinical disease, so no treatment is needed. For asymptomatic HPFH carriers, regular hematologic follow-up alone is sufficient. Care should be taken not to give unnecessary iron supplements or transfusions.
In HPFH/HbS compound heterozygosity where symptoms are mild because of high HbF, the standard treatment guidelines for sickle cell disease are followed, but treatment intensity is adjusted in light of the clinical course. Hydroxyurea may be used for additional HbF induction.
Understanding of the molecular mechanisms of HPFH has provided important insights for developing HbF induction treatment strategies for sickle cell disease and beta-thalassemia. Strategies such as BCL11A suppression, KLF1 modulation, and γ-promoter editing are being developed with the aim of reproducing the HPFH phenotype.
Gene therapies approved by the US FDA in 2023 (exagamglogene autotemcel, betibeglogene spartoparvovec) induce an increase in HbF through editing of the BCL11A erythroid enhancer or through beta-globin gene complementation. This is a direct clinical application of the molecular insights gained from HPFH research.
Simple heterozygous or homozygous HPFH is not a clinical disease, so the prognosis is completely normal. Affected individuals live healthy lives with a normal lifespan, normal quality of life, and no particular complications.
Combined HPFH/HbS shows a markedly milder course than simple HbSS and has a favorable prognosis. Combined HPFH/beta0 is also milder than beta0 homozygosity, but the clinical course varies with the HbF level.
HPFH is a key model for the development of HbF induction therapies. The success of BCL11A-editing gene therapy, which arose from research on HPFH mechanisms, has opened a new era in the treatment of sickle cell disease and beta-thalassemia. HPFH research will remain a key field in research on the treatment of hemoglobin disorders.
HPFH itself is not a clinical disease, but genetic counseling is needed regarding the possibility of compound heterozygosity with other globin gene abnormalities. When an HPFH carrier marries an HbS or beta-thalassemia carrier, counseling is provided on the possibility of clinically significant compound heterozygosity in their children.
HPFH alone is not an indication for prenatal diagnosis. However, in couples at risk of HPFH combining with another clinically significant globin variant, prenatal genetic testing is performed and sufficient counseling is provided on the prognosis of a compound heterozygous fetus.
Accurate diagnosis is important so that individuals diagnosed with HPFH are not misdiagnosed with thalassemia or other hemoglobin abnormalities and given unnecessary treatment (iron supplements, transfusions, etc.). It should be recognized that the HbF elevation associated with HPFH is not itself a target of treatment.